Coronavirus Disease 2019 (COVID-19) – Pipeline Review, H2 2020

 

Global Markets Direct’s, ‘Coronavirus Disease 2019 (COVID-19) – Pipeline Review, H2 2020’, provides an overview of the Coronavirus Disease 2019 (COVID-19) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronavirus Disease 2019 (COVID-19), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Coronavirus Disease 2019 (COVID-19)

The report reviews pipeline therapeutics for Coronavirus Disease 2019 (COVID-19) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Coronavirus Disease 2019 (COVID-19) therapeutics and enlists all their major and minor projects

The report assesses Coronavirus Disease 2019 (COVID-19) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Coronavirus Disease 2019 (COVID-19)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Coronavirus Disease 2019 (COVID-19)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coronavirus Disease 2019 (COVID-19) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

NA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coronavirus Disease 2019 (COVID-19) – Overview

Coronavirus Disease 2019 (COVID-19) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Coronavirus Disease 2019 (COVID-19) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coronavirus Disease 2019 (COVID-19) – Companies Involved in Therapeutics Development

4D Pharma Plc

A2A Pharmaceuticals Inc

AB Science SA

AbbVie Inc

Abivax SA

Abnova Corp

Aclaris Therapeutics Inc

Adaptive Biotechnologies Corp

Adjuvance Technologies Inc

Aerogen Ltd

Afecta Pharmaceuticals Inc

Agenus Inc

AI Therapeutics

AIkido Pharma Inc

AIM ImmunoTech Inc

AiVita Biomedical Inc

Akari Therapeutics Plc

Akebia Therapeutics Inc

Akers Biosciences Inc

Akshaya Bio Inc

Akston Biosciences Corp

Aldeyra Therapeutics Inc

Alexion Pharmaceuticals Inc

Alfasigma SpA

Algernon Pharmaceuticals Inc

AlloVir Inc

Alnylam Pharmaceuticals Inc

Alphamab Oncology

Altimmune Inc

Amarin Corp Plc

Amgen Inc

Ampio Pharmaceuticals Inc

AnGes Inc

Angion Biomedica Corp

Anixa Biosciences Inc

Ansun Biopharma Inc

AntiCancer Inc

APEIRON Biologics AG

Apellis Pharmaceuticals Inc

Apeptico Forschung und Entwicklung GmbH

Apogenix AG

Applied Therapeutics Inc

Aptorum Group Ltd

Arbutus Biopharma Corp

ARCA biopharma Inc

Arch Biopartners Inc

Arcturus Therapeutics Ltd

Argenx SE

Aridis Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Ascletis Pharma Inc

Aspire Health Science LLC

AstraZeneca Plc

Athersys Inc

Atossa Therapeutics Inc

Atreca Inc

Atriva Therapeutics GmbH

aTyr Pharma Inc

Avalon GloboCare Corp

Contd....

List of Tables

List of Tables

Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..3), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..4), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..5), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..6), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..7), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..8), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..9), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..10), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..11), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..12), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..13), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..14), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..15), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..16), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..17), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..18), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..19), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..20), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..21), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..22), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..23), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..24), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..25), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..26), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..27), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..28), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..29), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..30), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..31), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..32), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..33), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..34), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..35), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..3), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..4), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..5), H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Companies, H2 2020 (Contd..3), H2 2020

Products under Development by Companies, H2 2020 (Contd..4), H2 2020

Products under Development by Companies, H2 2020 (Contd..5), H2 2020

Products under Development by Companies, H2 2020 (Contd..6), H2 2020

Products under Development by Companies, H2 2020 (Contd..7), H2 2020

Products under Development by Companies, H2 2020 (Contd..8), H2 2020

Products under Development by Companies, H2 2020 (Contd..9), H2 2020

Products under Development by Companies, H2 2020 (Contd..10), H2 2020

Products under Development by Companies, H2 2020 (Contd..11), H2 2020

Products under Development by Companies, H2 2020 (Contd..12), H2 2020

Products under Development by Companies, H2 2020 (Contd..13), H2 2020

Products under Development by Companies, H2 2020 (Contd..14), H2 2020

Products under Development by Companies, H2 2020 (Contd..15), H2 2020

Products under Development by Companies, H2 2020 (Contd..16), H2 2020

Products under Development by Companies, H2 2020 (Contd..17), H2 2020

Products under Development by Companies, H2 2020 (Contd..18), H2 2020

Products under Development by Companies, H2 2020 (Contd..19), H2 2020

Products under Development by Companies, H2 2020 (Contd..20), H2 2020

Products under Development by Companies, H2 2020 (Contd..21), H2 2020

Products under Development by Companies, H2 2020 (Contd..22), H2 2020

Products under Development by Companies, H2 2020 (Contd..23), H2 2020

Products under Development by Companies, H2 2020 (Contd..24), H2 2020

Products under Development by Companies, H2 2020 (Contd..25), H2 2020

Products under Development by Companies, H2 2020 (Contd..26), H2 2020

Products under Development by Companies, H2 2020 (Contd..27), H2 2020

Products under Development by Companies, H2 2020 (Contd..28), H2 2020

Products under Development by Companies, H2 2020 (Contd..29), H2 2020

Products under Development by Companies, H2 2020 (Contd..30), H2 2020

Products under Development by Companies, H2 2020 (Contd..31), H2 2020

Products under Development by Companies, H2 2020 (Contd..32), H2 2020

Products under Development by Companies, H2 2020 (Contd..33), H2 2020

Products under Development by Companies, H2 2020 (Contd..34), H2 2020

Products under Development by Companies, H2 2020 (Contd..35), H2 2020

Products under Development by Companies, H2 2020 (Contd..36), H2 2020

Products under Development by Companies, H2 2020 (Contd..37), H2 2020

Products under Development by Companies, H2 2020 (Contd..38), H2 2020

Products under Development by Companies, H2 2020 (Contd..39), H2 2020

Products under Development by Companies, H2 2020 (Contd..40), H2 2020

Products under Development by Companies, H2 2020 (Contd..41), H2 2020

Products under Development by Companies, H2 2020 (Contd..42), H2 2020

Products under Development by Companies, H2 2020 (Contd..43), H2 2020

Contd….

List of Figures

List of Figures

Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports